PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsCefdinir
Cefdinir
Cefdinir (cefdinir) is a small molecule pharmaceutical. Cefdinir was first approved as Omnicef on 1997-12-04. It is used to treat bacterial infections, bacterial pneumonia, bacterial skin diseases, bronchitis, and escherichia coli infections amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
stomatognathic diseasesD009057
respiratory tract diseasesD012140
otorhinolaryngologic diseasesD010038
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Cefdinir (discontinued: Omnicef)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefdinir
Tradename
Company
Number
Date
Products
OMNICEFAbbVieN-050739 DISCN1997-12-04
1 products, RLD
OMNICEFAbbVieN-050749 DISCN1997-12-04
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cefdinirANDA2025-10-02
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
sinusitisEFO_0007486D012852J32
otitis mediaEFO_0004992D010033H66.9
bacterial infections—D001424A49
bacterial skin diseases—D017192—
escherichia coli infectionsEFO_1001318D004927B96.20
bronchitis—D001991J40
streptococcal infectionsEFO_1001476D013290—
tonsillitis—D014069—
bacterial pneumoniaEFO_1001272D018410J15.9
staphylococcal infections—D013203A49.01
Show 4 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DD: Third-generation cephalosporins
— J01DD15: Cefdinir
HCPCS
No data
Clinical
Clinical Trials
32 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———4————4
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCefdinir
INNcefdinir
Description
Cefdinir is a cephalosporin compound having 7beta-2-(2-amino-thiazol-4-yl)-2-[(Z)-hydroxyimino]-acetylamino- and 3-vinyl side groups. It has a role as an antibacterial drug. It is a cephalosporin and a ketoxime.
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\O)c3csc(N)n3)[C@H]2SC1
Identifiers
PDB—
CAS-ID91832-40-5
RxCUI—
ChEMBL IDCHEMBL927
ChEBI ID3485
PubChem CID6915944
DrugBankDB00535
UNII IDCI0FAO63WC (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Cefdinir
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,007 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3,449 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use